Huntington's Disease

The NeuraMetrix detection and monitoring digital biomarker allows Neurologists to
​​​​​​​micromanage and individualize the treatment of patients with Huntington's disease
old woman in wheelchair receives medication from nurseold woman in wheelchair receives medication from nurse

Huntington’s disease requires micromanagement

Huntington’s disease (HD) is a 100% genetically determined disorder which causes the progressive breakdown of nerve cells in the brain. It typically starts in a person's 30s or 40s. HD is known as the quintessential family disease because every child of a parent with HD has a 50/50 chance of inheriting the faulty gene.
The symptoms of HD are described as having ALS, Parkinson’s, and Alzheimer’s – simultaneously. HD manifests as a triad of motor, cognitive, and psychiatric symptoms which begin insidiously and progress over many years.

No cure exists, but drugs, physical therapy, and talk therapy can help manage some symptoms.

NeuraMetrix Huntington's research study

NeuraMetrix has concluded an HD study with one of the world-leading authorities on HD and the result has been published in an article “Monitoring the Phenotype in Huntington Disease by Analysis of Keyboard Typing During Real Life Computer Use” in the Journal of Huntington's Disease.
The results of this study are very encouraging as they indicate that the NeuraMetrix TC digital biomarker is able to separate those who have the mutation with no visible symptoms group into two distinct groups:
  • One group where the disease is not yet active
  • One group where the disease has already begun

NeuraMetrix TC has a wide range of benefits

With the easy to use NeuraMetrix digital biomarker, Neurologists can:
  • Begin treatment of patients where the disease has already begun but there are no visible symptoms
  • Monitor the effect of medication changes ​​​​​​​ (or other treatment changes) for an individual patient by accessing the patient’s chart a few weeks later. At that time, the Neurologist can determine if the changes had desired effect, no effect, or, at worse, adverse effects – all enabling the physician to take corrective action, if necessary.
  • Have more frequent interaction with their patients through convenient methods such as virtual meetings, phone, email, etc.
Resulting in:
  • Better and frequent management of the disease at a lower cost
NeuraMetrix is a member of:

"We train our Huntington’s patients intensively. I am amazed that the effects are so clearly shown in the inconsistency scores."

​​​​​​​- Dr. Christina Lang, M.D. – Department of Neurology, Universität Ulm, Germany